603142-80-9

Upstream product

• 106-37-6 1.4-dibromobenzene 
• 671818-85-2 (4S)-4-isobutyl-2-trifluoromethyl-oxazolidine 
• 896743-06-9 (S)-3-methyl-1-triethylsilanyloxymethyl-butylamine 
• 603142-79-6 [(S)-1-(tert-butyl-dimethyl-silanyloxymethyl)-3-methyl-butyl]-[2,2,2-trifluoro-eth-(E)-ylidene]-amine 
• 429-41-4 tetrabutyl ammonium fluoride 
• 896743-04-7 C₂₀H₃₃BrF₃NOSi 
• 7533-40-6 (S)-2-amino-4-methylpentan-1-ol 
• 896743-07-0 ((S)-3-methyl-1-triethylsilanyloxymethyl-butyl)-[2,2,2-trifluoro-eth-(E)-ylidene]amine 
• 896743-08-1 [(1S)-1-(4-bromo-phenyl)-2,2,2-trifluoro-ethyl]-((1S)-3-methyl-1-triethylsilanyloxymethyl-butyl)-amine 

Downstream Products

• 919352-63-9 (S)-2-(((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)amino)-4-methylpentanoic acid 
• 603139-12-4 (2S)-4-methyl-2-[(1S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)ethylamino]-pentanoic acid cyanomethyl-amide 

Relevant academic research and scientific papers

CYSTEINE PROTEASE INHIBITORS

A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is -C1-C5 straight or branched chain, optionally fluorinated, alkyl or -CH2CR5Csub

Diastereoselective arylithium addition to an α-trifluoromethyl imine. Practical synthesis of a potent cathepsin K inhibitor

A practical, chromatography-free synthesis of potent cathepsin K inhibitor 1 is described. The addition of 4-bromophenyllithium to an α- trifluoromethylimine derived from commercially available (S)-leucinol was accomplished in a highly diastereoselective

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

CATHEPSIN INHIBITORS

This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

4-AMINO-AZEPAN-3-ONE COMPOUNDS AS CATHEPSIN K INHIBITORS USEFUL IN THE TREATMENT OF OSTEOPOROSIS

This invention relates to compounds of formula (I) which are cysteine protease inhibitors, in particular, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as

Oxazolidine Ring Opening and Isomerization to (E)-Imines. Asymmetric Synthesis of Aryl-α-fluoroalkyl Amino Alcohols

(Matrix presented) A base-induced ring opening/imine isomerization/ diastereoselective organometallic addition sequence on 4-substituted 2-perfluoroalkyl-1,3-oxazolidines has been developed for the asymmetric synthesis of aryl α-perfluoroalkylamine deriva

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.